Telomir Pharmaceuticals, Inc.
TELO · XNASCIK 1971532fmd_0NZDJMAYX54C37V8ZBYZXJ5PCAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2022 to Sep 30, 2026, 16 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Research and development | 1 | 2 | 2 | 2 |
| Total operating expenses | 1 | 4 | 12 | 11 |
| Interest expense | – | 2 | 4 | – |
| Interest and investment income | – | – | 0 | 0 |
| Net income | (1) | (13) | (17) | (10) |